EMA
- Application: EMEA/H/C/004334
- Marketing authorisation holder: Bayer AG
- Local brand name: Aliqopa
- Indication: Treatment of adult patients with relapsed marginal zone lymphoma
- Pathway: orphan
- Status: withdrawn
🇪🇺 Aliqopa in European Union
Aliqopa (COPANLISIB) regulatory status in European Union.
Marketing authorisation
Aliqopa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Aliqopa approved in European Union?
Yes. EMA has authorised it.
Who is the marketing authorisation holder for Aliqopa in European Union?
Bayer AG holds the EU marketing authorisation.